Announcements Trials
Browse Landscape

Phase

Phase 2 24Phase 1 11Phase NA 7Phase 1/2 6Phase 3 3Phase 4 1

Status

Completed 56Active not recruiting 17Terminated 16Recruiting 10Withdrawn 6Unknown 5Not yet recruiting 3Suspended 1

Sponsor Class

OTHER 3NIH 2INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Lymphoid 2Gynecologic 2Breast 2Tumor-Agnostic 1Sarcoma 1

Conditions

Ovarian Neoplasms 2Triple Negative Breast Neoplasms 1Neoplasms 1Lymphoma, Primary Effusion 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Dendritic Cell Sarcoma, Interdigitating 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1Acromesomelic dysplasia, Maroteaux type 1

Interventions

Cyclophosphamide 28pembrolizumab 22Bevacizumab 18Fluorouracil 17Cisplatin 17Nivolumab 16Capecitabine 16Leucovorin 15Dexamethasone 14Carboplatin 13avelumab 12Oxaliplatin 12Radiosurgery 11Gemcitabine 11Rituximab 10Radiotherapy 10Lenalidomide 10ALT-803 10venetoclax 9fludarabine 9Taxes 9Omacor 9Azacitidine 9130-nm albumin-bound paclitaxel 9Paclitaxel 8Docetaxel 8Bortezomib 8fludarabine phosphate 7Melphalan 7Irinotecan 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1/2 × Withdrawn × Doxorubicin × Clear all
NCT03634150 2021-10-26

Safety and Efficacy of IV Nerofeâ„¢ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer

Immune System Key Ltd

Phase 1/2 Withdrawn
BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT01415765 2019-12-17

MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Withdrawn
LymphoidSarcoma

Acromesomelic dysplasia, Maroteaux type, Lymphoma, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT02228512 2018-08-31

Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas

National Institutes of Health Clinical Center (CC)

Phase 1/2 Withdrawn
Lymphoid

Lymphoma, Primary Effusion

NCT00562185 2017-11-20

Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian Cancer

University of Texas Southwestern Medical Center

Phase 1/2 Withdrawn
Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00124956 2017-09-11

Doxorubicin Pharmacokinetic (PK) Study

Boston Children's Hospital

Phase 1/2 Withdrawn
Tumor-Agnostic

Neoplasms

NCT00022230 2015-05-05

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Stage II or Stage III Breast Cancer

Roger Williams Medical Center

Phase 1/2 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡